• news.cision.com/
  • Attana/
  • Attana AB will support and collaborate with Prof. Salanti in developing a vaccine against Coronavirus

Attana AB will support and collaborate with Prof. Salanti in developing a vaccine against Coronavirus

Report this content

On March 7 Prof Ali Salanti and coworkers announced that they formed a consortium that have received a grant from EU to develop a vaccine against Coronavirus. The consortium will base the project on their previously developed method for vaccine development. Attana has been invited by Prof. Salanti to support the project with sensor chips for the development.

In collaboration with the University of Tübingen, Leiden University Medical Center, Wageningen University and the companies AdaptVac and ExpreS2ion, researchers from the University of Copenhagen have received a grant from the EU of EUR 2.7 million. The grant will be used to develop a vaccine against the new type of coronavirus disease, Covid-19, which at the moment is spreading worldwide.


Prof. Salanti, Ass.Prof. Morten Agertoug Nielsen and Ass. Prof. Adam Sander and several of their research colleagues have themselves invented and developed the vaccine technology which they are now using to create a vaccine against Covid-19. A small, but crucial, part of the Coronavirus is taken and attached on the surface of another not dangerous virus like particle, which will be the vaccine. When given as a vaccine, the aim is that the vaccinated person reacts to the virus like particle as though it was a coronavirus and generate an effective immune response that protects the body from the coronavirus.


The team of Prof. Salanti have previously demonstrated proof of principle of the vaccine technology with a . They are already well underway in the process of designing the vaccine, but it is very expensive to scale up a production and make sure that the vaccine is ready for use on humans. The grant will mainly be used to enable a rapid scale up the production of the vaccine for clinical tests. Attana has been invited and accepted to provide sensors chips to be used for the selection of the crucial proteins and as an additional quality control that the vaccine has remained it´s specificity after the production scale up. Attana will, if need, supply extra support in order to secure that the development goes as fast as possible.


Attana AB has no direct financial interests in this project. This is solely based on our long-term relation with Prof Salanti and his team and our wish to contribute to a solution of the current global situation due to the coronavirus.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com





Documents & Links